Month: January 2026
BRANFORD, Conn., Jan. 29, 2026 (GLOBE NEWSWIRE) — Sachem Capital Corp. (NYSE American: SACH) announced today the tax treatment for the Company’s distributions on its common stock (CUSIP: 78590A109) and preferred stock (CUSIP: 78590A505) paid with respect to the calendar year ended December 31, 2025:
COMMON STOCK TAX INFORMATION
Box 1a
Box 1b
Box 2a
Box 3
Box 5
Record Date
Payable Date
Rate PerShare
OrdinaryDividends PerShare
QualifiedDividends PerShare
Total CapitalGain PerShare
NondividendDistributionPer Share
Section 199ADividends PerShare3/17/2025
3/31/2025
$0.050000
$0.012362
$0.000000
$0.010840
$0.026798
$0.0123626/16/2025
6/30/2025
$0.050000
$0.012362
$0.000000
$0.010840
$0.026798
$0.0123629/15/2025
9/30/2025
$0.050000
$0.012362
$0.000000
$0.010840
$0.026798
$0.01236212/15/2025
12/30/2025
$0.050000
$0.012362
$0.000000
$0.010840
$0.026798
$0.012362
Total
$0.200000
$0.049448
$0.000000
$0.043360
$0.107194
$0.049448 PREFERRED...
Skye Bioscience Highlights Attributes of its Peripherally-restricted CB1 Inhibitor Antibody at Keystone Obesity Conference
Written by Customer Service on . Posted in Public Companies.
SAN DIEGO, Jan. 29, 2026 (GLOBE NEWSWIRE) — Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”) a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, today presented a poster titled “Investigating the Efficacy of Nimacimab Alone or in Combination with Tirzepatide, and as a Maintenance Therapy Post Tirzepatide Discontinuation in a Diet-Induced Obesity (DIO) Mouse Model” at Keystone’s conference, Obesity Therapeutics: Unlocking Benefits and Minimizing Side Effects.
Skye’s presentation addressed the following questions regarding the ability of its peripherally-restricted CB1-inhibitor antibody:Can nimacimab enhance optimal and suboptimal doses of incretin agonists?
How durable is nimacimab’s effect on weight loss after treatment discontinuation?
Can...
Chicago Atlantic Real Estate Finance Announces Tax Reporting Information for 2025 Distributions
Written by Customer Service on . Posted in Public Companies.
CHICAGO, Jan. 29, 2026 (GLOBE NEWSWIRE) — Chicago Atlantic Real Estate Finance, Inc. (NASDAQ: REFI) (“Chicago Atlantic” or the “Company”), a commercial mortgage real estate investment trust, today announced year-end tax reporting information for its 2025 distributions. Stockholders are urged to consult with their personal tax advisors as to their specific tax treatment.
Chicago Atlantic Real Estate Finance, Inc.CUSIP: 167239102Ticker: NASDAQ: REFIRecord Date
Payment Date
Cash Distribution (per share)
Dividend (1)
Ordinary Dividend(per share)
Qualified Dividends(per share)
Section 199A Dividends(per share)(2)3/31/2025
4/15/2025
$0.47
$0.47
$0.47
$0.00
$0.476/30/2025
7/15/2025
$0.47
$0.47
$0.47
$0.00
$0.479/30/2025
10/15/2025
$0.47
$0.47
$0.47
$0.00
$0.4712/31/2025
1/15/2026
$0.47
$0.47
$0.47
$0.00
$0.47 Pursuant...
Valley National Bancorp Reports Fourth Quarter 2025 Results
Written by Customer Service on . Posted in Public Companies.
NEW YORK, Jan. 29, 2026 (GLOBE NEWSWIRE) — Valley National Bancorp (NASDAQ:VLY), the holding company for Valley National Bank, today reported net income for the fourth quarter 2025 of $195.4 million, or $0.33 per diluted common share, as compared to the third quarter 2025 net income of $163.4 million, or $0.28 per diluted common share, and net income of $115.7 million, or $0.20 per diluted common share, for the fourth quarter 2024. Excluding all non-core income and charges, our adjusted net income (a non-GAAP measure) was $180.2 million, or $0.31 per diluted common share, for the fourth quarter 2025, $164.1 million, or $0.28 per diluted common share, for the third quarter 2025, and $75.7 million, or $0.13 per diluted common share, for the fourth quarter 2024. See further details below, including a reconciliation of our adjusted...
ConnectOne Bancorp, Inc. Reports Fourth Quarter and Full-Year 2025 Results
Written by Customer Service on . Posted in Public Companies.
Net Interest Margin Widens By 16 Basis PointsPerformance Metrics Gain MomentumBranch Rationalization to Result In 5 ClosuresCredit Trends Remain SolidDeclares Common and Preferred Dividends
ENGLEWOOD CLIFFS, N.J., Jan. 29, 2026 (GLOBE NEWSWIRE) — ConnectOne Bancorp, Inc. (Nasdaq: CNOB) (the “Company” or “ConnectOne”), parent company of ConnectOne Bank (the “Bank”), today reported net income available to common stockholders of $38.0 million for the fourth quarter of 2025 compared with $39.5 million for the third quarter of 2025 and $18.9 million for the fourth quarter of 2024. Diluted earnings per share were $0.75 for the fourth quarter of 2025 compared with $0.78 for the third quarter of 2025 and $0.49 for the fourth quarter of 2024. Full-year 2025 net income available to common stockholders was $74.4 million, compared to $67.8...
Talisker Reaches Major Safety Milestone Achieving One Year Operations Anniversary LTI Free at the Bralorne Gold Project
Written by Customer Service on . Posted in Public Companies.
TORONTO, Jan. 29, 2026 (GLOBE NEWSWIRE) — Talisker Resources Ltd. (“Talisker” or the “Company”) (TSX: TSK, OTCQB: TSKFF) is pleased to announce that it has reached a major workplace milestone – one year of operations without a lost time incident at the Bralorne Gold Project (“Bralorne”).
Mining services at the Mustang Mine commenced in January 2025 with Thyssen Mining Construction of Canada (“Thyssen”) undertaking mobilization, construction development followed by underground mining. Thyssen is a well-established mining contractor known for its proven track record of delivering high-quality, efficient mining services.
Richard Murrell, General Manager, Bralorne stated, “Every person at Thyssen and Bralorne has contributed to this accomplishment by working hard and working safely over this past year. Our “One Bralorne Team” has shown...
Coastal Financial Corporation Announces Fourth Quarter 2025 Results
Written by Customer Service on . Posted in Public Companies.
EVERETT, Wash., Jan. 29, 2026 (GLOBE NEWSWIRE) — Coastal Financial Corporation (Nasdaq: CCB) (the “Company”, “Coastal”, “we”, “our”, or “us”), the holding company for Coastal Community Bank (the “Bank”), through which it operates a community-focused bank segment (“community bank”) with an industry leading banking as a service (“BaaS”) segment (“CCBX”), today reported unaudited financial results for the quarter ended December 31, 2025, including net income of $12.6 million, or $0.82 per diluted common share, compared to $13.6 million, or $0.88 per diluted common share, for the three months ended September 30, 2025 and $13.4 million, or $0.94 per diluted common share, for the three months ended December 31, 2024, and $47.0 million, or $3.06 per diluted...
Nobel Closes Non-Brokered Private Placement Offering
Written by Customer Service on . Posted in Public Companies.
THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT AUTHORIZED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES.
TORONTO, Jan. 29, 2026 (GLOBE NEWSWIRE) — Nobel Resources Corp. (TSX–V: NBLC; OTCPK: NBTRF) (the “Company” or “Nobel”) announces that it has closed, on a fully-subscribed basis, its previously announced non-brokered private placement offering of 4,166,667 units (each a “Unit”) at a price of $0.06 per Unit for gross proceeds of $250,000 (the “Offering”).
Each Unit consists of one common share of the Company (each, a “Share”) and one-half of one common share purchase warrant (each whole warrant, a “Warrant”). Each Warrant entitles the holder to purchase one Share at a price of $0.075 until January 29, 2028. The securities issued pursuant to the Offering...
Kymera Therapeutics Announces First Patient Dosed in BREADTH Phase 2b Asthma Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader
Written by Customer Service on . Posted in Public Companies.
Data from the BREADTH Phase 2b asthma trial is expected to be reported in late-2027
Data from the ongoing parallel BROADEN2 Phase 2b atopic dermatitis trial is expected to be reported by mid-2027
WATERTOWN, Mass., Jan. 29, 2026 (GLOBE NEWSWIRE) — Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that it recently initiated dosing in its BREADTH Phase 2b clinical trial evaluating KT-621, an oral, highly selective, potent degrader of STAT6, in patients with moderate to severe eosinophilic asthma. The Company expects to report data from the BREADTH trial in late-2027.
“Untreated asthma can result in long-term medical complications. We continue to hear from physicians and patients that new treatment...
New Jersey orders additional 375 Xcelsior® clean-diesel buses from New Flyer
Written by Customer Service on . Posted in Public Companies.
ST. CLOUD, Minn., Jan. 29, 2026 (GLOBE NEWSWIRE) — (TSX: NFI, OTC: NFYEF, TSX: NFI.DB) NFI Group Inc. (NFI), a leader in bus and coach mobility solutions, and subsidiary New Flyer of America Inc. (New Flyer), has received an additional order from New Jersey Transit Corporation (NJ TRANSIT) for 375 Xcelsior® 40-foot, clean-diesel transit buses. This order is part of a larger, previously announced multi-phase fleet replacement program, with orders placed in the third and fourth quarters of 2025.
The original contract, awarded in the first quarter of 2024, included a base order of 550 Xcelsior 40-foot, clean-diesel transit buses to be delivered in three distinct lots, along with options for an additional 750 units. With this newly announced order, NJ TRANSIT has now completed the full base order of 550 buses, leaving all 750 option...
